登录 | 注册    关注公众号  
微信公众号
搜索
 > 【LILRB1】

LILRB1信息

英文名称:Leukocyte immunoglobulin-like receptor B1
中文名称:白细胞免疫球蛋白样受体B1
靶点别称:Leukocyte Immunoglobulin Like Receptor B1,LIR-1,MIR-7,ILT2,LIR1,Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 1 Soluble Isoform,PIR-B,Leukocyte immunoglobulin-like receptor 1,MIR7,PIRB,CD85j,Immunoglobulin-like transcript 2,Leukocyte Immunoglobulin-Like Receptor, Subfamily B (With TM And ITIM Domains), Member 1,Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 1,Monocyte/Macrophage Immunoglobulin-Like Receptor 7,CD85 Antigen-Like Family Member J,Myeloid Inhibitory Receptor 7,
上市药物数量:0
临床药物数量:4
最高研发阶段:临床二期

LILRB1产品列表

ACRO质量管理体系
 
评论(6)
CDJ-C52H3|Cynomolgus LILRB1 / CD85j / ILT2 Protein, His Tag
  1. 185XXXXXXX2
  2. 1人赞
  3. 用于建立blocking assay,效果要比其他两家和内部自己表达的好了不少,非特异性少,top值高,Window不错,推荐使用
  4. 2022-01-14
CDJ-H5252|Human LILRB1 / CD85j / ILT2 Protein, Fc Tag (MALS verified)
  1. 181XXXXXXX6
  2. 0人赞
  3. 这款蛋白非常好,我们用来进行ELISA筛选实验,实验数据非常好,重复性也非常好,让我们筛选出好的分子,大大提高了我们的工作效率。
  4. >
  5. 2022-08-10
CDJ-H82F7|Biotinylated Human LILRB1 / CD85j / ILT2 Protein, Fc,Avitag™
  1. 920XXXXXXX
  2. 0人赞
  3. This sample was highly pure which was very helpful in selection campaigns to find specific molecules. We did our own QC on the sample to verify purity and it matched up perfectly with SDS-PAGE and SEC-MALS that is provided on the website. Shipping was quick to prevent delays in our project timelines. This sample was sent lyophilized and very easy to reconstitute for use.
  4. 2022-04-20
 

LILRB1分子别名

CD85J,LILRB1,CD85,ILT2,LIR1,MIR7

LILRB1分子背景

CD85 antigen-like family member J (CD85J) is also known as Leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1 or LIR-1), Immunoglobulin-like transcript 2 (ILT-2), Monocyte/macrophage immunoglobulin-like receptor 7 (MIR7), which belongs to leukocyte immunoglobulin-like receptor (LIR) family. CD85J / LILRB1 Contains 4 Ig-like C2-type (immunoglobulin-like) domains. CD85J / LIR-1 is expressed predominantly on B-cells and monocytes. CD85J is receptor for class I MHC antigens and recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles and is also receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response. CD85J / LILRB1 interaction with HLA-B or HLA-E leads to inhibition of the signal triggered by FCER1A and inhibits serotonin release. CD85J / LILRB1 inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

LILRB1临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
NGM-707 NGM-707 临床二期 Merck & Co, Ngm Biopharmaceuticals Inc 卵巢癌, 胃癌, 肾细胞癌, 头颈部鳞状细胞癌, 食道癌, 胶质母细胞瘤, 间皮组织肿瘤, 胆管上皮癌, 乳腺癌, 结直肠癌, 胰腺导管癌, 非小细胞肺癌, 宫颈癌, 黑色素瘤 详情
BND-22 BND-22; SAR-444881 临床二期 Biond Biologics Ltd, 赛诺菲 肿瘤 详情
IOS-1002 ios-H2 临床一期 ImmunOs Therapeutics AG 实体瘤, 血液肿瘤 详情
AGEN-1571 AGEN-1571 临床一期 安帝君斯公司 实体瘤, 肿瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定